【英文】美国智库ITIF报告：抓住癌早期筛查的变革机遇（45页）

英文研究报告 2021年04月28日 06:49 管理员

This report begins by examining the social and economic costs cancer inflicts. It discusses the importance of early cancer detection and moves on to an exploration of how MCED technologies work, evidence of their effectiveness to date, the benefits they are capable of providing, and why it’s important the United States remain the global leader in this field. It then analyzes the regulatory and coverage environment before concluding by providing recommendations for how policymakers can enact policies enabling this transformative technology to flourish, including by passing legislation creating a pathway to ensure timely Medicare coverage of MCED screening exams.

THE INDIVIDUAL, SOCIAL, AND ECONOMIC COSTS OF CANCER Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells.1 It remains one of America’s, and global societies’, greatest health challenges. Cancer is responsible for almost one in six deaths globally.2 The global cancer burden is expected to surpass 20 million new yearly cases by 2025.3 Cancer is the second-most common cause of death in the United States, exceeded only by heart disease, although cancer is expected to become the leading cause of American fatalities by 2030.

Likewise, among adults ages 35 to 70, while cardiovascular disease remains the leading cause of mortality globally, “mortality from cancer will probably become the leading cause of death” in the near future.4 Experts predict the year 2021 will see 1.9 million new cancer cases diagnosed in the United States, with over 600,000 Americans expected to perish from the disease, which translates to about 1,650 deaths per day.